This trial is trying to understand how safe and effective a new targeted therapy is on its own and in combination with a standard immunotherapy (Pembrolizumab) in people with advanced non-small cell lung cancer who have not received previous treatment.
This trial is treating patients with non-small cell lung cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naÃ¯ve Subjects With Advanced or Metastatic PD-L1 High (TPS â‰¥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)
Daiichi Sankyo Ltd.
Eligible participants will be randomised to receive 200 mg pembrolizumab with or without 6.0mg/kg Datopotamab Deruxtecan (Dato-DXd).Pembrolizumab and/or Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
Recruiting Hospitals Read More